Ulcerative Colitis

Only 29.5% of sampled CBD users claimed any wellness benefit.

The longitudinal study included 209 children, one of the largest samples in the world for a study on this topic.

The study observed 50 women taking infliximab, adalimumab, and vedolizumab.

TLR9 activation shows potential as a target for ulcerative colitis and warrants further testing.

This edition from the 10 Year Plan features perspective from leadership at WGO and Crohn's & Colitis Foundation, as well as survey results from gastroenterologists.

Testing all IBD patients for CMV can lead to a concerning overconsumption of resources as well as a delay in treatment.

The cut points for LCT and nCD64 in Crohn’s disease were not previously known.

Fecal material transplantation for the management of patients with IBD demonstrates a response rate of 53.8% with a complete remission of 37%.

Low levels of COC associated with a higher likelihood of outpatient flares that required corticosteroids, hospitalizations, and surgical interventions.

A sibling control group showed similar results as a general population control group.

A gastroenterologist discusses how gastrointestinal symptoms are manifesting in patients with COVID-19.

Dr. Erica Brenner talks about how gastroenterologists should safely return to screening and diagnosing patients.

An expert discusses how a registry of gastrointestinal symptoms is leading research during COVID-19.

A gastroenterologist discusses some of the findings regarding COVID-19 and gastrointestinal symptoms.

Firmicutes bacteria can help produce metabolites that maintain intestinal barriers and mucosal immunity.

Nearly two-thirds of COVID-19 patients have gastrointestinal symptoms.

Patients in the multidisciplinary-care group were more likely to experience a 50% or higher reduction in all Gastrointestinal Symptom Severity Index symptom clusters than the patients who were in the standard-care group.

In a sample of patients treated with laparoscopic ileocecal resection, 42% (n = 29) of patients did not require additional Crohn’s disease-related medication, while 48% (n = 14) were given prophylactic immunomodulator therapy.

Ozanimod could soon be added to the ever growing stable of potential treatments for Crohn’s disease.